Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
G.A. Greendale, N.P. Lee, E.R. Arriola.
The menopause.
Lancet, 353 (1999), pp. 571-580
[2.]
N.F. Woods, E.S. Mitchell.
Anticipating menopause: observations from the Seattle Midlife Women's Health Study.
Menopause, 6 (1999), pp. 167-173
[3.]
O.L. Svendsen, C. Hassager, C. Christiansen.
Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women.
Am J Med, 95 (1993), pp. 121-140
[4.]
M.S. LeBoff, L. Kohlmeier, S. Hurwitz, J. Franklin, J. Wright, J. Howacki.
Occult vitamin D deficiency in postmenopausal US women with acute hip fracture.
JAMA, 281 (1999), pp. 1505-1511
[5.]
S. McNagny.
Prescribing hormone replacement therapy for menopausal women.
Ann Intern Med, 131 (1999), pp. 605-616
[7.]
Novak's gynecology (12.a ed.),
[8.]
Clinical gynecologic endocrinology and infertility (5.a ed.),
[9.]
L. Weinstein, C. Bewtra, J.C. Gallagher.
Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient.
Am J Obstet Gynecol, 162 (1990), pp. 1534-1539
[10.]
T.K. Chung, S.K. Yip, P. Lam, A.M. Chang, C.J. Haines.
A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms.
Maturitas, 25 (1996), pp. 115-123
[11.]
C.A. Staropoli, J.A. Flaws, T.I. Bush, A.W. Moulton.
Predictors of menopausal hot flashes.
J Womens Healthy, 7 (1998), pp. 1149-1155
[12.]
C. Egarter, M. Sator, P. Berghammer, J. Huber.
Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women.
Int J Gynaecol Obstet, 64 (1999), pp. 281-286
[13.]
K. Yaffe, G. Sawaya, I. Lieberburg, D. Grady.
Estrogen therapy in postmenopausal women: effects on cognitive function and dementia.
JAMA, 279 (1998), pp. 688-695
[14.]
S. Waring, W.A. Rocca, R.C. Petersen, P.C. O'Brian, E.G. Tangalos, E. Kokmen.
Postmenopausal estrogen replacement therapy and risk of Alzheimer disease: a population-based study.
Neurology, 52 (1999), pp. 965-970
[15.]
E.E. Calle.
Hormone replacement therapy and colorectal cancer: interpreting the evidence.
Cancer Causes Control, 8 (1997), pp. 127-129
[16.]
The Eye-Disease Case-Control Study Group.
Risk factors for neovascular age-related macular degeneration.
Arch Ophthalmol, 110 (1992), pp. 1705-1708
[17.]
T.B. Pearlstein.
Hormones and depression: what age the facts about premenstrual syndrome, menopause, and hormone replacement therapy?.
Am J Obstet Gynecol, 173 (1995), pp. 646-653
[18.]
B.L. Harlow, D.W. Cramer, K.M. Annis.
Association of medically treated depression an age at natural menopause.
Am J Epidemiol, 141 (1995), pp. 1170-1179
[19.]
N.E. Avis, D. Brambilla, S.M. McKinlay, K. Vass.
A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study.
Ann Epidemiol, 4 (1994), pp. 214-220
[20.]
P.A. Kaufert, P. Gilbert, R. Tate.
The Manitoba Project: a re-examination of the link between menopause and depression.
Maturitas, 14 (1992), pp. 143-155
[21.]
L. Nicol-Smith.
Causality, menopause, and depression: a critical review of the literature.
BMJ, 313 (1996), pp. 1229-1232
[22.]
H. Joffe, L.S. Cohen, J. Hennen, K. Carlson.
The perimenopause is a period of risk for depressive symptoms in middle-aged women [NR 13].
The American Psychiatric Association 152nd Annual Meeting, Washington, DC, (1999),
[23.]
C. Cooper, E.J. Atkinson, W.M. O'Fallon, L.J. Melton.
Incidence of clinical diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989.
J Bone Min Res, 7 (1992), pp. 221-227
[24.]
R.P. Heaney.
Bone mass, bone loss, and osteoporosis prophylaxis.
Ann Intern Med, 128 (1998), pp. 313-314
[25.]
S.L. Hui, C.W. Slemenda, C.C. Johnston Jr..
Age and bone mass as predictors of fracture in a prospective study.
J Clin Invest, 81 (1988), pp. 1804-1809
[27.]
L. Sampietro-Colom, C. Almazán, A. Granados.
Evaluación de la densitometría ósea.
Agència d'Avaluació de Tecnologia Mèdica, mayo, (1993),
[28.]
D. Marshall, O. Johnell, H. Wedel.
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.
BMJ, 312 (1996), pp. 1254-1259
[29.]
Physician's Guide to prevention and treatment of osteoporosis.
[30.]
N.F. Col, M.H. Eckman, R.H. Karas, S.G. Panker, R.J. Goldberg, E.M. Ross, et al.
Patient-specific decisions about hormone replacement therapy in postmenopausal women.
JAMA, 277 (1997), pp. 1140-1147
[31.]
K. Grady, S.M. Rubin, D.B. Petitti, C.S. Fox, D. Black, B. Ettinger, et al.
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Ann Intern Med, 117 (1992), pp. 1016-1037
[32.]
B. Ettinger, D. Black, B. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, et al.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA, 282 (1999), pp. 637-645
[33.]
J. Studd, I. Arnala, P.M. Kicovic, D. Zamblera, H. Kroger, N. Holland, et al.
A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures.
Obstet Gynecol, 92 (1998), pp. 574-579
[34.]
S.A. Beardsworth, C.E. Kearney, D.W. Purdy.
Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.
Br J Obstet Gynaecol, 106 (1999), pp. 678-683
[35.]
S.L. Crawford, C.B. Johannes.
The epidemiology of cardiovascular disease in postmenopausal women.
J Clin Endocrinol Metab, 84 (1999), pp. 1803-1806
[36.]
G.A. Colditz, W.C. Willet, M.J. Stampfer, B. Rosner, F.E. Speizer, C.H. Hennekens, et al.
Menopause and the risk of coronary heart disease in women.
N Engl J Med, 316 (1987), pp. 1105-1110
[37.]
T. Bush.
The epidemiology of cardiovascular disease in post menopausal women.
Ann N Y Acad Sci, 592 (1990), pp. 263-271
[38.]
H. Tunstall-Pedoe.
Myth and paradox of coronary risk and the menopause.
Lancet, 351 (1998), pp. 1425-1427
[39.]
L. Tomás Abadal.
Riesgo cardiovascular en la menopausia: mito, paradoja o realidad. Importancia de las observaciones clínicas frente a la interpretación de los datos estadísticos.
Rev Esp Cardiol, 52 (1999), pp. 463-466
[41.]
G.M. Rosano, G. Panina.
Cardiovascular pharmacology of hormone replacement therapy.
Drugs Aging, 15 (1999), pp. 219-234
[42.]
The Writing Group for the PEPI Trial.
Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
JAMA, 273 (1995), pp. 199-208
[43.]
W.M. Van Baal, R.G. Smoleders, M.J. Van der Mooren, T. Teerlink, P. Kenemans.
Hormone replacement therapy and plasma homocysteine levels.
Obstet Gynecol, 94 (1999), pp. 485-491
[44.]
A. Tchernof, J. Calles-Escandon, C. Sites, E.T. Poehlman.
Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy.
Coron Arter Disk, 9 (1998), pp. 503-511
[45.]
S.R. Lindheim, D.M. Duffy, T. Kijima, M.A. Vijod, F.Z. Stanazyk, R.A. Lobo, et al.
The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women.
Fertil Steril, 62 (1994), pp. 1176-1180
[46.]
T. Raudaskoski, C. Tomas, T. Laatikainen.
Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel.
Acta Obstet Gynecol Scand, 78 (1999), pp. 540-545
[47.]
A.C. Duncan, H. Lyall, R.N. Roberts, J.R. Petrie, M.J. Perera, S. Monaghan, et al.
The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women.
J Clin Endocrinol Metabol, 84 (1999), pp. 2402-2409
[48.]
C. Castelo-Branco, E.F. Casals, F. Figueras, A. Sanjuán, J.J. Vicente, et al.
Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AL and B.
Menopause, 6 (1999), pp. 92-97
[49.]
K. Rödstrom, C. Bengtsson, L. Lissner, C. Björkelund.
Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden.
BMJ, 319 (1999), pp. 890-893
[50.]
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group.
JAMA, 280 (1998), pp. 605-613
[51.]
Collaborative Group on Hormonal Factors in Breast Cancer.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.
Lancet, 350 (1997), pp. 1047-1059
[52.]
K.K. Steinberg, S.B. Thacker, S.J. Smith, D.F. Stroup, M.M. Zack, W.D. Flanders, et al.
A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.
JAMA, 265 (1991), pp. 1985-1990
[53.]
Europe Menopause Society.
European consensus development conference on menopause.
Hum Reprod, 11 (1996), pp. 975-979
[54.]
S.M. Gapstur, M. Morrow, T.A. Sellers.
Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study.
JAMA, 281 (1999), pp. 2091-2097
[55.]
S. Stallard, J.C. Litherland, C.M. Cordiner, H.M. Dobson, W.D. George, E.A. Mallon, et al.
Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study.
BMJ, 320 (2000), pp. 348-349
[56.]
C. Schairer, J. Lubin, R. Troisi, M.H. Sturgeon, L. Brinton, R. Hoover, et al.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
JAMA, 283 (2000),
Copyright © 2000. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
